WuXi Biologics is Officially Listed on the Hong Kong Stock Exchange

Tuesday, June 13, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

HONG KONG, June 12, 2017 /PRNewswire/ -- On June 13,

2017 Hong Kong time, WuXi Biologics (Cayman) Inc. ("the Company"; stock code: 2269.HK) was officially listed during a grand listing ceremony at the Main Board of The Stock Exchange
of Hong Kong. Dr. Ge Li, Group Chairman and CEO of WuXi AppTec and Chairman of WuXi Biologics, Dr. Chris Chen, Executive Director and CEO of WuXi Biologics, and representatives from the Company, its intermediary institutions, and its collaborative partners, witnessed this important development milestone of the Company.

Headquartered in Wuxi city, Jiangsu province, with three operation sites in Wuxi, Shanghai and Suzhou respectively, WuXi Biologics is the only open-access biologics capability and technology enabling platform in the world with end-to-end solutions, empowering anyone and any company to discover, develop and manufacture biologics from concept to commercial manufacturing.

"The successful listing of WuXi Biologics on the Hong Kong Stock Exchange marks another important milestone in the history of the Company," said Dr. Ge Li. "This will further accelerate our expansion in capabilities and capacities, strengthen our leadership position as the most comprehensive and integrated enabling platform, and will allow us to better enable innovation to benefit patients worldwide."

"The successful listing on the Main Board of the Stock Exchange of Hong Kong is a new starting point for WuXi Biologics," said Dr. Chris Chen. "We will further standardize the operation and management of the Company, strictly abide by the Listing Rules, and diligently fulfill various regulatory obligations as a public company. We will reciprocate the trust of our collaborative partners, investors, and employees with strong performance, sustainable growth, and value for patients and society."

About WuXi Biologics

WuXi Biologics, a WuXi AppTec Affiliate, is a leading open-access technology capability and technology platform to enable anyone and any company to develop biologics. WuXi Biologics provides our worldwide clients with the necessary expertise, quality and capacities to develop biologic drugs from concept to commercialization. Along with our WuXi AppTec affiliates, we provide the world with the ONE true single-source approach that saves our clients critical time and money. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi's Biologics services, please visit: http://www.wuxibiologics.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/wuxi-biologics-is-officially-listed-on-the-hong-kong-stock-exchange-300472744.html

SOURCE WuXi Biologics



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store